The COVID-19 crisis has impacted many industries and driven new collaborations in the healthcare industry and beyond to ensure continuity of supply and business operations. Though COVID-19 is still very much alive as a public health crisis, antitrust enforcement has largely resumed business as usual, albeit in a virtual capacity. Since our March 27, 2020 alert, government authorities in both the US and the EU have largely resumed their normal merger review procedures under the antitrust laws.
November 16, 2020
